Skip to Content
Current OncologyCurrent Oncology
  • Case Report
  • Open Access

1 December 2014

8 Pages

Gemcitabine-Based Regimen for Primary Ovarian Angiosarcoma with MYC Amplification

,
,
,
,
,
and
1
Obstetrics and Gynecology, Shizuoka Saiseikai General Hospital, Shizuoka, Japan
2
Cell Biology and Anatomy, Hamamatsu University School of Medicine, Shizuoka, Japan
3
Pathology, Shizuoka Saiseikai General Hospital, Shizuoka, Japan
*
Author to whom correspondence should be addressed.

Abstract

Angiosarcoma is a rare and aggressive type of sarcoma, and primary angiosarcoma of the ovary is extremely rare. We report the case of a 29-year-old woman who was diagnosed with ovarian angiosarcoma and possible bone metastases. We treated this patient with a gemcitabine-based regimen as postoperative adjuvant chemotherapy, after which she achieved at least 7 years of progression-free survival, an extremely long duration given the aggressive features of this tumour. We retrospectively performed immunohistochemical analyses and fluorescence in situ hybridization to make a pathology diagnosis and to investigate the tumour features. MYC amplification and c-Myc protein overexpression were positively detected. It might be possible to correlate the effectiveness of the gemcitabine-based chemotherapeutic regimen with MYC gene amplification and c-Myc protein overexpression.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.